SecSonar.com

Emergent BioSolutions Inc. (EBS)

Emergent BioSolutions Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Emergent BioSolutions Inc. (EBS) is a Biotechnology company based in US with a market capitalization of $478.8M. Revenue declined 28.8% year-over-year and the company generated $156.8M in free cash flow. This page tracks EBS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 900 employees · IPO Nov 15, 2006

Valuation

Valuation & price

$7.94 · as of May 17, 2026 · -42.9% vs 52w high

8.6

P/E ratio

Latest-FY diluted EPS

0.92

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$13.36$9.62$5.88Jul 25Dec 25Jul 26Jul 7, 25$6.62Jul 9, 25$7.33Jul 11, 25$7.36Jul 15, 25$6.93Jul 17, 25$7.28Jul 21, 25$6.94Jul 23, 25$7.66Jul 25, 25$7.17Jul 29, 25$6.50Jul 31, 25$5.88Aug 4, 25$5.95Aug 6, 25$6.03Aug 11, 25$8.16Aug 13, 25$8.79Aug 15, 25$8.84Aug 19, 25$9.19Aug 21, 25$9.32Aug 25, 25$9.20Aug 27, 25$8.59Aug 29, 25$8.30Sep 3, 25$7.83Sep 5, 25$7.58Sep 9, 25$8.26Sep 11, 25$8.23Sep 16, 25$7.83Sep 18, 25$7.94Sep 22, 25$8.18Sep 24, 25$8.29Sep 26, 25$8.91Sep 30, 25$8.82Oct 2, 25$9.19Oct 6, 25$9.14Oct 8, 25$9.89Oct 10, 25$9.07Oct 14, 25$9.09Oct 16, 25$9.40Oct 21, 25$9.45Oct 23, 25$9.66Oct 27, 25$9.69Oct 29, 25$9.40Oct 31, 25$12.48Nov 4, 25$10.09Nov 6, 25$10.27Nov 10, 25$10.99Nov 12, 25$10.81Nov 14, 25$10.11Nov 18, 25$10.12Nov 20, 25$9.08Nov 25, 25$10.95Nov 28, 25$11.17Dec 2, 25$10.85Dec 4, 25$12.05Dec 8, 25$11.87Dec 10, 25$11.56Dec 12, 25$11.41Dec 16, 25$12.19Dec 18, 25$12.30Dec 22, 25$12.81Dec 24, 25$12.63Dec 29, 25$12.22Jan 2, 26$12.51Jan 6, 26$13.15Jan 8, 26$13.36Jan 12, 26$12.39Jan 14, 26$12.54Jan 16, 26$10.99Jan 21, 26$11.50Jan 23, 26$11.95Jan 27, 26$12.22Jan 29, 26$11.90Feb 2, 26$11.71Feb 4, 26$11.41Feb 9, 26$11.03Feb 11, 26$11.03Feb 13, 26$10.83Feb 18, 26$10.78Feb 20, 26$10.93Feb 24, 26$10.96Feb 26, 26$11.10Mar 2, 26$8.99Mar 4, 26$8.77Mar 6, 26$8.29Mar 10, 26$8.39Mar 12, 26$8.13Mar 17, 26$8.08Mar 19, 26$8.08Mar 23, 26$8.05Mar 25, 26$8.21Mar 27, 26$7.93Mar 31, 26$8.30Apr 2, 26$8.23Apr 7, 26$7.85Apr 9, 26$8.45Apr 13, 26$8.24Apr 15, 26$8.66Apr 17, 26$8.81Apr 22, 26$8.29Apr 24, 26$8.03Apr 28, 26$8.23Apr 30, 26$8.23May 4, 26$8.54May 6, 26$9.10May 8, 26$9.50May 12, 26$8.50May 14, 26$8.21May 18, 26$8.13May 20, 26$8.15May 22, 26$8.45May 28, 26$9.18Jun 1, 26$8.49Jun 3, 26$7.93Jun 5, 26$8.07Jun 9, 26$7.95Jun 11, 26$8.39Jun 15, 26$8.29Jun 17, 26$8.14Jun 22, 26$7.85Jun 24, 26$8.43Jun 26, 26$8.53Jul 2, 26$8.28
$5.6352-week range$13.90
Loading valuation history…

Fundamentals

Key fundamentals

$478.8M

Market cap

-28.8%

Revenue growth (YoY)

47.2%

Gross margin

$156.8M

Free cash flow (USD)

$366.7M

Net debt

0.9%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$488.8MFY 2017$560.9MFY 2018$782.4MFY 2019$1.1BFY 2020$1.6BFY 2021$1.8BFY 2022$1.1BFY 2023$1.0BFY 2024$1.0BFY 2025$742.9M
$488.8M$742.9M

Free cash flow by year

2016 → 2025

FY 2016$-22.8MFY 2017$153.3MFY 2018$-30.3MFY 2019$101.1MFY 2020$395.0MFY 2021$96.1MFY 2022$-149.9MFY 2023$-257.9MFY 2024$35.8MFY 2025$156.8M
-$22.8M$156.8M

Gross margin by year

2021 → 2025

FY 202144.7%FY 202242.3%FY 202334.3%FY 202436.0%FY 202547.2%
44.7%47.2%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

5

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 1, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $25K · 10b5-1 PlanWilliams Paul Anthony · SVP, Products Business · $25.2KJul 2, 2026Filing
  • 8-K eventContract ModificationJun 29, 2026Filing
  • Insider sellInsider Sell $144K · 10b5-1 PlanZoon Kathryn C · Director · $144.5KMay 4, 2026Filing
  • Insider sellInsider Sell $128K · 10b5-1 PlanKatkin Keith · Director · $128.2KMay 4, 2026Filing
  • Insider sellInsider Sell $130K · 10b5-1 PlanDeGolyer Donald W · Director · $130KMay 4, 2026Filing
  • Insider sellInsider Sell $116K · 10b5-1 PlanDayal Sujata Tyagi · Director · $115.6KMay 4, 2026Filing
  • Quarterly report10-Q FiledMay 1, 2026Filing
  • 8-K eventStock Incentive Plan AmendedApr 30, 2026Filing
  • 8-K eventEarnings ReleaseApr 30, 2026Filing
  • 8-K eventCredit Agreement AmendmentApr 17, 2026Filing

Questions

Frequently asked questions

What is Emergent BioSolutions Inc.'s market cap?

Emergent BioSolutions Inc. (EBS) has a market capitalization of $478.8M.

What is EBS's P/E ratio?

EBS trades at a price-to-earnings ratio of 8.6, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is EBS's price-to-book (P/B) ratio?

EBS trades at 0.92 times book value per share.

Are insiders buying EBS stock?

SEC Form 4 filings show no open-market insider buys at Emergent BioSolutions Inc. in the last 90 days (5 sells).

Same arena

Related companies in Biotechnology

OCGN

Ocugen, Inc.

$470M

AUTL

Autolus Therapeutics plc

$492.4M

CTNM

Contineum Therapeutics, Inc. Class A Common Stock

$499.1M

DBVT

DBV Technologies S.A.

$454.8M

FDMT

4D Molecular Therapeutics, Inc.

$506.6M

ASMB

Assembly Biosciences, Inc.

$441.9M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.